The literature review shows a low adhesion of urologists to the recommendations of learned societies in the imaging work-up of localized prostate cancer (CaP), especially for low and intermediate risks of the D'Amico classification. We analyzed the adhesion of urologists in the Hérault region (France) to the CCAFU 2016/2018, 2018/2020 recommendations.
From the Hérault Onco Urology Registry (RHESOU) database, we identified localized CaP diagnosed between 01/01/2017 and 31/12/2019, and then classified them into 3 distinct risk groups according to the D'Amico classification. We compared the imaging workup performed by each patient to the CCAFU 2016/2018, 2018/2020 recommendations, according to the risk group.
Of the 2,049 localized CaPs included in our study, 591 belonged to the low-risk group, 1059 to the intermediate-risk group, and 399 to the high-risk group. In the low-risk group 45.2% of the cases did not follow the CCAFU 2016/2018, 2018/2020 recommendations in the imaging workup, 77.3% in the intermediate-risk group and 80.9% in the high-risk group. For our entire study, 1,408 patients (68.7%) had an imaging workup that did not follow the CCAFU recommendations.
Our results show a low adhesion of urologists to the CCAFU recommendations in the imaging assessment of localized CaP. The causes of this non-adhesion are multifactorial and difficult to analyze.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2022 Nov 04 [Epub ahead of print]
B Trétarre, S-G Trouche-Sabatier, A-S Foucan, N Abdo, G Poinas, X Rébillard, D Azria, F Iborra
Registre des tumeurs de l'Hérault, 208 rue des apothicaires, 34298 Montpellier cedex 5, France; CERPOP, université de Toulouse, Inserm, UPS, Toulouse, France. Electronic address: ., Registre des tumeurs de l'Hérault, 208 rue des apothicaires, 34298 Montpellier cedex 5, France., CHU Lapeyronie, Montpellier, France., Clinique Beau Soleil, Montpellier, France., Inserm U 1194, ICM, université Montpellier, Montpellier, France., Registre des tumeurs de l'Hérault, 208 rue des apothicaires, 34298 Montpellier cedex 5, France; CHU Lapeyronie, Montpellier, France.